Therapeutic Management of COVID-19 Patients: A systematic review
(چکیده مقاله) :
Abstract :
Background: SARS-CoV-2 is the causative agent of COVID-19; that has been declared
a global pandemic by the WHO in 2020. The COVID-19 treatment guidelines vary in
each country, and yet there is no approved therapeutic for COVID-19.
Aims of the study: this review aimed to report any evidence of therapeutics used for the
management of COVID-19 patients in clinical practice since the emergence of the virus.
Methods: A systematic review protocol was developed based on PRISMA Statement.
Articles for review were selected from electronic databases (Embase, Medline and
Google Scholar). Readily accessible peer-reviewed, full articles in English published
from December 1st , 2019 to March 26th , 2020 were included. The search terms included
combinations of: COVID, SARS-COV-2, glucocorticoids, convalescent plasma, antiviral
and antibacterial. There were no restrictions on the type of study design eligible for
inclusion.
Results: As of March 26th, 2020, of the initial manuscripts identified (n=449); forty-one
studies were included. These consisted of clinical trials (n=3), case reports (n=7), case
series (n=10), retrospective (n=11) and prospective (n=10) observational studies. Thirtysix
studies were conducted in China (88%).
The most commonly reported medicine in this systematic review was corticosteroids
(n=25), followed by Lopinavir (n=21) and Oseltamivir (n=16).
Conclusions: This is the first systematic review to date related to the therapeutics used in
COVID-19 patients. Only 41 research articles on COVID-19 and therapeutics were found
eligible to be included, most conducted in Chi
a global pandemic by the WHO in 2020. The COVID-19 treatment guidelines vary in
each country, and yet there is no approved therapeutic for COVID-19.
Aims of the study: this review aimed to report any evidence of therapeutics used for the
management of COVID-19 patients in clinical practice since the emergence of the virus.
Methods: A systematic review protocol was developed based on PRISMA Statement.
Articles for review were selected from electronic databases (Embase, Medline and
Google Scholar). Readily accessible peer-reviewed, full articles in English published
from December 1st , 2019 to March 26th , 2020 were included. The search terms included
combinations of: COVID, SARS-COV-2, glucocorticoids, convalescent plasma, antiviral
and antibacterial. There were no restrictions on the type of study design eligible for
inclusion.
Results: As of March 26th, 2020, of the initial manuscripts identified (n=449); forty-one
studies were included. These consisted of clinical trials (n=3), case reports (n=7), case
series (n=10), retrospective (n=11) and prospective (n=10) observational studies. Thirtysix
studies were conducted in China (88%).
The most commonly reported medicine in this systematic review was corticosteroids
(n=25), followed by Lopinavir (n=21) and Oseltamivir (n=16).
Conclusions: This is the first systematic review to date related to the therapeutics used in
COVID-19 patients. Only 41 research articles on COVID-19 and therapeutics were found
eligible to be included, most conducted in Chi
(توضیحات تکمیلی) :
(توضیحات تکمیلی) :
Description :
مقاله ISI انگلیسی اصلی
سال انتشار: 2020
فایل ISI انگلیسی اصلی ، با فرمت Pdf
تعداد صفحات فایل ISI انگلیسی اصلی: 42 صفحه
سال انتشار: 2020
فایل ISI انگلیسی اصلی ، با فرمت Pdf
تعداد صفحات فایل ISI انگلیسی اصلی: 42 صفحه
Authors / Descriptions(نویسندگان/توضیحات): سال انتشار 2020 \ مقاله ISI انگلیسی اصلی \ نویسندگان: Mansour Tobaiqy, Mohammed Qashqary, Shrooq Al-Dahery, Alaa Mujallad, Almonther Abdullah Hershan, Mohammad Azhar Kamal, Nawal Helmi
Sent date(تاریخ ارسال) :
1399/01/29 | 4/17/2020
Number of visits(تعداد بازدید):
916
Key words (کلمات کلیدی):
SARS-CoV-2, COVID-19, Hydroxychloroquine, Arbidol hydrochloride, Corticosteroids, Convalescent Plasma Therapy
Number of pages(تعداد صفحات) :
42
| نظرات کاربران در مورد این آگهی | |
|
در حال حاضر هیچ نظری ثبت نگردیده است .
|
|